Fascaplysin as a specific inhibitor for CDK4: insights from molecular modelling.
Cyclin-dependent kinases (CDKs) play a key role in the cell cycle and are important anti-cancer drug targets. The natural product fascaplysin inhibits CDK4 with surprising selectivity (IC(50) = 0.4 µM) compared to the close homolog CDK2 (IC(50) = 500 µM). Free energy calculations of the positively c...
Guardado en:
Autores principales: | Muhammad Imtiaz Shafiq, Thomas Steinbrecher, Ralf Schmid |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c622997dbf9b4663940d1dddc8902028 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Lindsey R. Pack, et al.
Publicado: (2021) -
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Carla L. Alves, et al.
Publicado: (2021) -
Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
por: Erin R. Scheidemann, et al.
Publicado: (2021) -
Quantifying CDK inhibitor selectivity in live cells
por: Carrow I. Wells, et al.
Publicado: (2020) -
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
por: Carla L. Alves, et al.
Publicado: (2021)